The Experts below are selected from a list of 14262 Experts worldwide ranked by ideXlab platform
Morberg Cathrine Melsaether - One of the best experts on this subject based on the ideXlab platform.
-
effect of the probiotic strain bifidobacterium animalis subsp lactis bb 12 on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort a randomised double blind placebo controlled parallel group trial
British Journal of Nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Peter J. Whorwell, Michelsen Birgit, S A Mullerlissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).
-
Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
The British journal of nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Birgit Michelsen, Peter J. Whorwell, Stefan Müller-lissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P
Dorte Eskesen - One of the best experts on this subject based on the ideXlab platform.
-
effect of the probiotic strain bifidobacterium animalis subsp lactis bb 12 on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort a randomised double blind placebo controlled parallel group trial
British Journal of Nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Peter J. Whorwell, Michelsen Birgit, S A Mullerlissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).
-
Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
The British journal of nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Birgit Michelsen, Peter J. Whorwell, Stefan Müller-lissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P
Lillian Jespersen - One of the best experts on this subject based on the ideXlab platform.
-
effect of the probiotic strain bifidobacterium animalis subsp lactis bb 12 on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort a randomised double blind placebo controlled parallel group trial
British Journal of Nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Peter J. Whorwell, Michelsen Birgit, S A Mullerlissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).
-
Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
The British journal of nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Birgit Michelsen, Peter J. Whorwell, Stefan Müller-lissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P
Peter J. Whorwell - One of the best experts on this subject based on the ideXlab platform.
-
effect of the probiotic strain bifidobacterium animalis subsp lactis bb 12 on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort a randomised double blind placebo controlled parallel group trial
British Journal of Nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Peter J. Whorwell, Michelsen Birgit, S A Mullerlissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).
-
Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and Abdominal Discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
The British journal of nutrition, 2015Co-Authors: Dorte Eskesen, Lillian Jespersen, Birgit Michelsen, Peter J. Whorwell, Stefan Müller-lissner, Morberg Cathrine MelsaetherAbstract:The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and Abdominal Discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of Abdominal Discomfort and symptoms. GI well-being, defined as global relief of Abdominal Discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P
Deborah K. Armstrong - One of the best experts on this subject based on the ideXlab platform.
-
validation of fact gog ad subscale for ovarian cancer related Abdominal Discomfort a gynecologic oncology group study
Gynecologic Oncology, 2008Co-Authors: Lari Wenzel, Helen Q. Huang, David Cella, Joan L. Walker, Deborah K. ArmstrongAbstract:Abstract Objective To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing Abdominal Discomfort in patients undergoing treatment for ovarian cancer. Methods A four-item questionnaire was developed for use in Gynecologic Oncology Group (GOG) protocol 172. It was administered to patients with advanced ovarian cancer treated on this protocol with intravenous (IV) cisplatin/paclitaxel or a combination of intravenous and intraperitoneal (IP) cisplatin/paclitaxel (IV/IP) prior to randomization, before cycle 4, 3–6 weeks after cycle 6, and 12 months after cycle 6. The subscale was evaluated in patients receiving IV/IP therapy for internal consistency, concurrent validity, sensitivity to treatment differences, and responsiveness to Abdominal Discomfort grading. Results Internal consistency coefficients were 0.83 and 0.87 at baseline and pre-cycle 4 assessments, respectively; the average inter-item correlation was 0.61 at the pre-cycle 4 assessment. Item correlation with other scales ranged from 0.00–0.44. This subscale was able to distinguish those graded to have physician-rated Abdominal pain compared to those without clinician-reported Discomfort. Conclusion The four-item AD subscale reliably and validly assesses ovarian cancer-specific Abdominal Discomfort, and captures Abdominal symptom responses to IV and IV/IP cisplatin/paclitaxel treatments.
-
Validation of FACT/GOG-AD subscale for ovarian cancer-related Abdominal Discomfort: A Gynecologic Oncology Group study
Gynecologic oncology, 2008Co-Authors: Lari Wenzel, Helen Q. Huang, David Cella, Joan L. Walker, Deborah K. ArmstrongAbstract:Abstract Objective To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing Abdominal Discomfort in patients undergoing treatment for ovarian cancer. Methods A four-item questionnaire was developed for use in Gynecologic Oncology Group (GOG) protocol 172. It was administered to patients with advanced ovarian cancer treated on this protocol with intravenous (IV) cisplatin/paclitaxel or a combination of intravenous and intraperitoneal (IP) cisplatin/paclitaxel (IV/IP) prior to randomization, before cycle 4, 3–6 weeks after cycle 6, and 12 months after cycle 6. The subscale was evaluated in patients receiving IV/IP therapy for internal consistency, concurrent validity, sensitivity to treatment differences, and responsiveness to Abdominal Discomfort grading. Results Internal consistency coefficients were 0.83 and 0.87 at baseline and pre-cycle 4 assessments, respectively; the average inter-item correlation was 0.61 at the pre-cycle 4 assessment. Item correlation with other scales ranged from 0.00–0.44. This subscale was able to distinguish those graded to have physician-rated Abdominal pain compared to those without clinician-reported Discomfort. Conclusion The four-item AD subscale reliably and validly assesses ovarian cancer-specific Abdominal Discomfort, and captures Abdominal symptom responses to IV and IV/IP cisplatin/paclitaxel treatments.
